{"id":147587,"date":"2024-12-19T14:58:56","date_gmt":"2024-12-19T09:28:56","guid":{"rendered":"https:\/\/pwonlyias.com\/stage\/?post_type=mains-answer-writing&#038;p=147587"},"modified":"2024-12-20T11:38:45","modified_gmt":"2024-12-20T06:08:45","slug":"the-interplay-between-affordability-and-quality-in-indias-generic-pharmaceutical","status":"publish","type":"mains-answer-writing","link":"https:\/\/pwonlyias.com\/stage\/mains-answer-writing\/the-interplay-between-affordability-and-quality-in-indias-generic-pharmaceutical","title":{"rendered":"Critically examine the interplay between affordability and quality in India&#8217;s generic pharmaceutical landscape. Highlight the challenges posed by decentralized drug regulations, variations in manufacturing standards, and non-uniform enforcement mechanisms. (15 M, 250 words)"},"content":{"rendered":"<table style=\"width: 99.4967%;\">\n<tbody>\n<tr>\n<td style=\"width: 100%;\">\n<h3><span style=\"font-size: 16pt;\"><b>Core Demand of the Question<\/b><\/span><\/h3>\n<ul>\n<li><span style=\"font-weight: 400;\">Examine the affordability in India&#8217;s generic pharmaceutical landscape.<\/span><\/li>\n<li><span style=\"font-weight: 400;\">Examine the limitation in balancing affordability with quality in India&#8217;s generic pharmaceutical landscape.<\/span><\/li>\n<li><span style=\"font-weight: 400;\">Highlight the challenges posed by decentralized drug regulations, variations in manufacturing standards, and non-uniform enforcement mechanisms.<\/span><\/li>\n<li><span style=\"font-weight: 400;\">Suggest a way ahead<\/span><\/li>\n<\/ul>\n<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<h2><span style=\"font-size: 18pt;\"><b>Answer<\/b><\/span><\/h2>\n<p><b>India&#8217;s generic pharmaceutical<\/b><span style=\"font-weight: 400;\"> sector, which supplies over <\/span><b>60% <\/b><span style=\"font-weight: 400;\">of the <\/span><b>world&#8217;s vaccines <\/b><span style=\"font-weight: 400;\">and<\/span><b> 20%<\/b><span style=\"font-weight: 400;\"> of all <\/span><b>generic medicines<\/b><span style=\"font-weight: 400;\">, is central to global healthcare affordability. However, the interplay between affordability and quality faces significant challenges. <\/span><b>Decentralized drug regulations, <\/b><span style=\"font-weight: 400;\">variations in manufacturing standards, and inconsistent enforcement mechanisms lead to discrepancies in drug quality, with about <\/span><b>1.5%<\/b><span style=\"font-weight: 400;\"> of medicines <\/span><b>failing quality tests<\/b><span style=\"font-weight: 400;\"> in the country. This impacts <\/span><b>patient safety<\/b><span style=\"font-weight: 400;\"> and undermines<\/span><b> healthcare outcomes.<\/b><\/p>\n<p style=\"text-align: center;\"><span class=\"vc_button\"><a href=\"https:\/\/www.pw.live\/batches\/upsc?utm_source=seo+upsc+batch&#038;utm_medium=seo+upsc&#038;utm_campaign=seo&#038;utm_id=upsc\" target=\"_blank\" rel=\"noopener\">Enroll now for UPSC Online Course<\/a><\/span><\/p>\n<h2><span style=\"font-size: 18pt;\"><b>Affordability in India\u2019s Generic Pharmaceutical Landscape<\/b><\/span><\/h2>\n<ul>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><b>Cost-effectiveness through economies of scale: <\/b><span style=\"font-weight: 400;\">India leverages its vast manufacturing base and low production costs to produce affordable generic medicines, reducing healthcare expenditure.<\/span><span style=\"font-weight: 400;\"><br \/>\n<\/span><b>For example:<\/b><span style=\"font-weight: 400;\"> Generic medicines sold under the <\/span><b>Pradhan Mantri Bhartiya Janaushadhi Pariyojana<\/b><span style=\"font-weight: 400;\"> have saved consumers<\/span><b> \u20b930,000 crore <\/b><span style=\"font-weight: 400;\">over the last decade.<\/span><\/li>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><b>Reduction in out-of-pocket expenditure: <\/b><span style=\"font-weight: 400;\">Affordable generics contribute to minimizing out-of-pocket healthcare costs, which constitute a significant share of health expenditure in India.<\/span><span style=\"font-weight: 400;\"><br \/>\n<\/span><b>For example:<\/b><span style=\"font-weight: 400;\"> In 2021-22, <\/span><b>out-of-pocket healthcare expenditure <\/b><span style=\"font-weight: 400;\">stood at <\/span><b>39.4% of total health expenditure,<\/b><span style=\"font-weight: 400;\"> where generics played a key role in providing cost-effective solutions.<\/span><\/li>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><b>Increased treatment adherence: <\/b><span style=\"font-weight: 400;\">Low-cost generics improve patient adherence to prescribed treatments, ensuring consistent care and better health outcomes.<\/span><span style=\"font-weight: 400;\"><br \/>\n<\/span><b>For example:<\/b><span style=\"font-weight: 400;\"> Affordable antidiabetic generics enable broader access to essential treatment for chronic conditions in low-income populations.<\/span><\/li>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><b>Export of affordable medicines globally: <\/b><span style=\"font-weight: 400;\">India&#8217;s generic pharmaceutical industry supplies cost-effective medicines to developing countries, enhancing global healthcare accessibility.<\/span><span style=\"font-weight: 400;\"><br \/>\n<\/span><b>For example:<\/b><span style=\"font-weight: 400;\"> India is often referred to as the <\/span><b>\u201cpharmacy of the world\u201d <\/b><span style=\"font-weight: 400;\">for its role in supplying affordable generics internationally, especially during the <\/span><b>COVID-19 pandemic.<\/b><\/li>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><b>Support from government programs: <\/b><span style=\"font-weight: 400;\">Schemes like the <\/span><b>Pradhan Mantri Bhartiya Janaushadhi Pariyojana<\/b><span style=\"font-weight: 400;\"> promote affordability through government-subsidized generic drug stores.<\/span><span style=\"font-weight: 400;\"><br \/>\n<\/span><b>For example:<\/b> <b>Generic<\/b><span style=\"font-weight: 400;\"> medicines worth <\/span><b>\u20b95,600 crore<\/b><span style=\"font-weight: 400;\"> were sold under this scheme by August 2024.<\/span><\/li>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><b>Bioequivalence to branded drugs: <\/b><span style=\"font-weight: 400;\">Generics are designed to be bioequivalent to their branded counterparts, offering the same therapeutic effects at a fraction of the price.<\/span><span style=\"font-weight: 400;\"><br \/>\n<\/span><b>For example:<\/b><span style=\"font-weight: 400;\"> Generic<\/span><b> antibiotics<\/b><span style=\"font-weight: 400;\"> and <\/span><b>antihypertensive drugs<\/b><span style=\"font-weight: 400;\"> provide similar efficacy to branded ones, making treatment accessible to economically weaker sections.<\/span><\/li>\n<\/ul>\n<h2><span style=\"font-size: 18pt;\"><b>Limitations in Balancing Affordability with Quality<\/b><\/span><\/h2>\n<ul>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><b>Quality control lapses: <\/b><span style=\"font-weight: 400;\">Inconsistent quality standards and regulatory oversight undermine the effectiveness and safety of generic drugs.<\/span><span style=\"font-weight: 400;\"><br \/>\n<\/span><b>For example:<\/b><span style=\"font-weight: 400;\"> A study by<\/span><b> PGIMER<\/b><span style=\"font-weight: 400;\"> found that generic<\/span><b> itraconazole<\/b><span style=\"font-weight: 400;\"> achieved therapeutic drug levels in only <\/span><b>29%<\/b><span style=\"font-weight: 400;\"> of <\/span><b>patients <\/b><span style=\"font-weight: 400;\">within two weeks, compared to <\/span><b>73% <\/b><span style=\"font-weight: 400;\">for the<\/span><b> innovator drug.<\/b><\/li>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><b>Variability in excipients and manufacturing processes: <\/b><span style=\"font-weight: 400;\">Differences in excipients and production methods can impact drug stability, absorption, and bioavailability, compromising therapeutic outcomes.<\/span><span style=\"font-weight: 400;\"><br \/>\n<\/span><b>For instance:<\/b><span style=\"font-weight: 400;\"> Generic capsules with<\/span><b> uneven pellet sizes <\/b><span style=\"font-weight: 400;\">showed delayed drug release, requiring dose escalation or switching to the innovator drug.<\/span><\/li>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><b>Regulatory arbitrage due to decentralization: <\/b><span style=\"font-weight: 400;\">Fragmented drug regulation by <\/span><b>State Drug Regulatory Authorities <\/b><span style=\"font-weight: 400;\">(SDRAs) allows manufacturers to exploit weaker oversight, leading to inconsistent quality.<\/span><span style=\"font-weight: 400;\"><br \/>\n<\/span><b>For example:<\/b><span style=\"font-weight: 400;\"> The <\/span><b>Central Drugs Standard Control Organisation<\/b><span style=\"font-weight: 400;\"> (CDSCO) has limited power, relying on States to enforce quality standards effectively.<\/span><\/li>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><b>Inadequate enforcement of stability testing: <\/b><span style=\"font-weight: 400;\">Stability testing mandated by the CDSCO in 2018 is inconsistently implemented, resulting in generics with poor shelf life and efficacy.<\/span><span style=\"font-weight: 400;\"><br \/>\n<\/span><b>For instance:<\/b><span style=\"font-weight: 400;\"> Drugs approved before 2018 often <\/span><b>bypass these requirements<\/b><span style=\"font-weight: 400;\">, perpetuating the availability of substandard medications.<\/span><\/li>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><b>Lax impurity standards in Indian Pharmacopoeia: <\/b><span style=\"font-weight: 400;\">Higher permissible impurity levels compared to U.S. and EU standards compromise the safety of generics in India.<\/span><span style=\"font-weight: 400;\"><br \/>\n<\/span><b>For example:<\/b><span style=\"font-weight: 400;\"> The rejection of stricter ICH guidelines by the CDSCO and Pharmacopoeia Commission on cost grounds highlights this gap.<\/span><\/li>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><b>Bioequivalence thresholds for narrow therapeutic index drugs: <\/b><span style=\"font-weight: 400;\">The allowable bioequivalence range of <\/span><b>80%-125%<\/b><span style=\"font-weight: 400;\"> is insufficient for drugs with narrow therapeutic indices, leading to subtherapeutic effects or adverse reactions.<\/span><span style=\"font-weight: 400;\"><br \/>\n<\/span><b>For instance:<\/b><span style=\"font-weight: 400;\"> Fluctuations in drug levels for<\/span><b> life-saving medications<\/b><span style=\"font-weight: 400;\"> like <\/span><b>anticoagulants <\/b><span style=\"font-weight: 400;\">have been observed in generic versions due to inadequate thresholds.<\/span><\/li>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><b>Lack of centralization in drug regulation: <\/b><span style=\"font-weight: 400;\">India\u2019s decentralized drug regulation system hinders the establishment of uniform quality standards.<\/span><span style=\"font-weight: 400;\"><br \/>\n<\/span><b>For example:<\/b><span style=\"font-weight: 400;\"> Recommendations by the<\/span> <b>Bhatia (1954), Hathi (1975),<\/b><span style=\"font-weight: 400;\"> and<\/span><b> Mashelkar (2003) committees<\/b><span style=\"font-weight: 400;\"> for centralized oversight have yet to be fully implemented, perpetuating regulatory disparities.<\/span><\/li>\n<\/ul>\n<h2><span style=\"font-size: 18pt;\"><b>Challenges Posed by Decentralized Drug Regulations<\/b><\/span><\/h2>\n<ul>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><b>Inconsistent Quality Standards Across States<\/b><span style=\"font-weight: 400;\">: India&#8217;s decentralized drug regulation system allows State Drug Regulatory Authorities (SDRAs) to set their own standards, leading to discrepancies in drug quality.<\/span><span style=\"font-weight: 400;\"><br \/>\n<\/span><b>For instance:<\/b> <b>Weak oversight<\/b><span style=\"font-weight: 400;\"> in some states allows manufacturers to exploit regulatory gaps, leading to the circulation of substandard generics.<\/span><\/li>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><b>Limited Authority of the Central Regulatory Body<\/b><span style=\"font-weight: 400;\">: The Central Drugs Standard Control Organisation (CDSCO) lacks enforcement power, reducing its ability to ensure uniform quality nationwide.<\/span><span style=\"font-weight: 400;\"><br \/>\n<\/span><b>For instance:<\/b><span style=\"font-weight: 400;\"> The CDSCO can only recommend<\/span><b> actions against manufacturers,<\/b><span style=\"font-weight: 400;\"> leaving critical enforcement to State authorities, which may lack resources or willpower.<\/span><\/li>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><b>Regulatory Arbitrage<\/b><span style=\"font-weight: 400;\">: Manufacturers may relocate to states with less stringent regulations to avoid stricter compliance.<\/span><span style=\"font-weight: 400;\"><br \/>\n<\/span><b>For instance:<\/b><span style=\"font-weight: 400;\"> Pharmaceutical companies have been known to shift operations to states with lax inspection systems, undermining the quality assurance process.<\/span><\/li>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><b>Lack of Coordination Between States and Centre<\/b><span style=\"font-weight: 400;\">: Fragmented authority leads to duplication of efforts and delays in addressing quality concerns.<\/span><span style=\"font-weight: 400;\"><br \/>\n<\/span><b>For instance:<\/b><span style=\"font-weight: 400;\"> A delayed response to<\/span><b> substandard <\/b><span style=\"font-weight: 400;\">itraconazole generics due to <\/span><b>poor coordination <\/b><span style=\"font-weight: 400;\">highlighted the inefficiencies of decentralized regulation.<\/span><\/li>\n<\/ul>\n<p style=\"text-align: center;\"><span class=\"vc_button\"><a href=\"https:\/\/store.pw.live\/govt-entrance-exams\/upsc-books?utm_source=SEO&#038;utm_medium=PW+Live&#038;utm_campaign=UPSC+CSE+Books\" target=\"_blank\" rel=\"noopener\"><span style=\"font-weight: 400;\">Check Out UPSC CSE Books From PW Store<\/span><\/a><\/span><\/p>\n<h2><span style=\"font-size: 18pt;\"><b>Challenges Posed by Variations in Manufacturing Standards<\/b><\/span><\/h2>\n<ul>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><b>Differences in Excipients<\/b><span style=\"font-weight: 400;\">: Variability in binders, fillers, and coatings impacts drug absorption and therapeutic outcomes.<\/span><span style=\"font-weight: 400;\"><br \/>\n<\/span><b>For example:<\/b><span style=\"font-weight: 400;\"> The <\/span><b>PGIMER <\/b><span style=\"font-weight: 400;\">study showed that generics of itraconazole had fewer and unevenly sized pellets, compromising bioavailability.<\/span><\/li>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><b>Inconsistent Manufacturing Processes<\/b><span style=\"font-weight: 400;\">: Variations in equipment and methods like granulation and compression lead to fluctuations in drug properties.<\/span><span style=\"font-weight: 400;\"><br \/>\n<\/span><b>For example:<\/b><span style=\"font-weight: 400;\"> Generic drugs releasing <\/span><b>active pharmaceutical ingredients (API)<\/b><span style=\"font-weight: 400;\"> more rapidly caused drug level fluctuations, affecting efficacy.<\/span><\/li>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><b>Subpar Tablet Design<\/b><span style=\"font-weight: 400;\">: Physical defects, such as irregular tablet hardness and porosity, disrupt drug disintegration and absorption.<\/span><span style=\"font-weight: 400;\"><br \/>\n<\/span><b>For example:<\/b><span style=\"font-weight: 400;\"> Defects in generic <\/span><b>itraconazole <\/b><span style=\"font-weight: 400;\">capsules delayed therapeutic drug levels compared to innovator drugs.<\/span><\/li>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><b>Lack of Advanced Technology in Production<\/b><span style=\"font-weight: 400;\">: Many manufacturers lack access to state-of-the-art technologies for consistent manufacturing.<\/span><span style=\"font-weight: 400;\"><br \/>\n<\/span><b>For example:<\/b><span style=\"font-weight: 400;\"> Small-scale units in India often use<\/span><b> outdated equipment<\/b><span style=\"font-weight: 400;\">, making it difficult to replicate the innovator\u2019s sustained-release mechanisms.<\/span><\/li>\n<\/ul>\n<h2><span style=\"font-size: 18pt;\"><b>Challenges Posed by Non-Uniform Enforcement Mechanisms<\/b><\/span><\/h2>\n<ul>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><b>Inadequate Stability Testing<\/b><span style=\"font-weight: 400;\">: Limited enforcement of stability protocols leads to substandard drugs, especially in diverse climatic conditions.<\/span><span style=\"font-weight: 400;\"><br \/>\n<\/span><b>For example:<\/b><span style=\"font-weight: 400;\"> Stability testing mandates by the<\/span><b> CDSCO<\/b><span style=\"font-weight: 400;\"> in <\/span><b>2018<\/b><span style=\"font-weight: 400;\"> remain poorly implemented, with pre-2018 generics escaping scrutiny.<\/span><\/li>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><b>Higher Permissible Impurity Levels<\/b><span style=\"font-weight: 400;\">: The <\/span><b>Indian Pharmacopoeia<\/b><span style=\"font-weight: 400;\"> allows higher impurity thresholds than international standards, risking drug safety.<\/span><span style=\"font-weight: 400;\"><br \/>\n<\/span><b>For example:<\/b><span style=\"font-weight: 400;\"> Rejection of<\/span><b> stricter ICH guidelines<\/b><span style=\"font-weight: 400;\"> due to cost concerns perpetuates the presence of impure drugs in the market.<\/span><\/li>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><b>Lack of Periodic Reassessment<\/b><span style=\"font-weight: 400;\">: Generics approved in the past are rarely reassessed for quality compliance under current standards.<\/span><span style=\"font-weight: 400;\"><br \/>\n<\/span><b>For example:<\/b><span style=\"font-weight: 400;\"> Many long-standing generic drugs in India do not meet the updated regulatory benchmarks for bioequivalence and stability.<\/span><\/li>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><b>Shortage of Testing Facilities<\/b><span style=\"font-weight: 400;\">: Insufficient central drug-testing laboratories hampers the effective monitoring of drug quality.<\/span><span style=\"font-weight: 400;\"><br \/>\n<\/span><b>For instance:<\/b><span style=\"font-weight: 400;\"> Overburdened state labs fail to conduct <\/span><b>timely inspections,<\/b><span style=\"font-weight: 400;\"> allowing substandard drugs to persist in the supply chain.<\/span><\/li>\n<\/ul>\n<h2><span style=\"font-size: 18pt;\"><b>Way Ahead to Address Challenges in India&#8217;s Generic Pharmaceutical Landscape<\/b><\/span><\/h2>\n<ul>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><b>Centralize Drug Regulation:<\/b><span style=\"font-weight: 400;\"> Establish a centralized regulatory body, like the <\/span><b>USFDA<\/b><span style=\"font-weight: 400;\">, to ensure uniform enforcement of quality standards across India.<\/span><span style=\"font-weight: 400;\"><br \/>\n<\/span><b>For example:<\/b><span style=\"font-weight: 400;\"> The <\/span><b>EMA\u2019s centralized framework<\/b><span style=\"font-weight: 400;\"> has maintained consistent drug standards across Europe, ensuring uniformity.<\/span><\/li>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><b>Stability Testing:<\/b><span style=\"font-weight: 400;\"> Mandate uniform <\/span><b>stability testing protocols<\/b><span style=\"font-weight: 400;\"> for all generic drugs to ensure efficacy under diverse climatic conditions.<\/span><span style=\"font-weight: 400;\"><br \/>\n<\/span><b>For example:<\/b><span style=\"font-weight: 400;\"> The <\/span><b>WHO guidelines<\/b><span style=\"font-weight: 400;\"> for tropical regions can serve as a model for India\u2019s varied climatic zones.<\/span><\/li>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><b>Manufacturing Standards<\/b><span style=\"font-weight: 400;\">: Implement stricter <\/span><b>manufacturing standards<\/b><span style=\"font-weight: 400;\"> for excipients and formulations to ensure consistency.<\/span><\/li>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><b>Enforcement Mechanisms:<\/b><span style=\"font-weight: 400;\"> Equip <\/span><b>State Drug Regulatory Authorities (SDRAs)<\/b><span style=\"font-weight: 400;\"> with standardized training and clear enforcement guidelines.<\/span><span style=\"font-weight: 400;\"><br \/>\n<\/span><b>For example:<\/b><span style=\"font-weight: 400;\"> Disparities in regulatory oversight, like those in <\/span><b>Uttar Pradesh<\/b><span style=\"font-weight: 400;\">, affect drug quality consistency across states.<\/span><\/li>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><b>Public Confidence:<\/b><span style=\"font-weight: 400;\"> Launch nationwide awareness campaigns to <\/span><b>build public confidence<\/b><span style=\"font-weight: 400;\"> in the safety and efficacy of generics.<\/span><span style=\"font-weight: 400;\"><br \/>\n<\/span><b>For example:<\/b><span style=\"font-weight: 400;\"> The <\/span><b>PMBJP<\/b><span style=\"font-weight: 400;\"> has improved trust in generics by making affordable medicines available to a wide population.<\/span><\/li>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><b>Technology Integration: <\/b><span style=\"font-weight: 400;\">Leverage <\/span><b>digital tools<\/b><span style=\"font-weight: 400;\"> like blockchain to ensure transparency and traceability in drug manufacturing and distribution.<\/span><span style=\"font-weight: 400;\"><br \/>\n<\/span><b>For example:<\/b> <b>DAVA (Drug Authentication and Verification Application)<\/b><span style=\"font-weight: 400;\"> has been effective in reducing counterfeit medicines in India.<\/span><\/li>\n<\/ul>\n<p style=\"text-align: center;\"><span class=\"vc_button\"><a href=\"https:\/\/www.pw.live\/batches\/upsc\/pw-only-ias?utm_source=seo+upsc+batch&#038;utm_medium=seo+upsc&#038;utm_campaign=seo&#038;utm_id=upsc\" target=\"_blank\" rel=\"noopener\">Enroll now for UPSC Online Classes<\/a><\/span><\/p>\n<p><span style=\"font-weight: 400;\">Achieving a balance between affordability and quality in India&#8217;s generic pharmaceutical sector requires <\/span><b>addressing regulatory fragmentation <\/b><span style=\"font-weight: 400;\">and enhancing manufacturing standards. A <\/span><b>unified regulatory framework, consistent enforcement,<\/b><span style=\"font-weight: 400;\"> and investment in<\/span><b> quality assurance<\/b><span style=\"font-weight: 400;\"> can help bridge the gap. A collaborative approach can ensure that both affordability and quality are prioritized for the betterment of public health.<\/span><\/p>\n<div class=\"vc_table_green\"><\/p>\n<table style=\"width: 99.6375%;\">\n<tbody>\n<tr>\n<td style=\"width: 111.19%; text-align: center;\" colspan=\"2\"><span style=\"font-size: 18pt;\"><b>Also Read<\/b><\/span><\/td>\n<\/tr>\n<tr>\n<td style=\"width: 49.797%; text-align: center;\"><a href=\"https:\/\/pwonlyias.com\/stage\/editorial-analysis\/\" target=\"_blank\" rel=\"noopener\"><b>UPSC Daily Editorials<\/b><\/a><\/td>\n<td style=\"width: 61.393%; text-align: center;\"><a href=\"https:\/\/pwonlyias.com\/stage\/daily-current-affairs\/\" target=\"_blank\" rel=\"noopener\"><b>UPSC Daily Current Affairs<\/b><\/a><\/td>\n<\/tr>\n<tr>\n<td style=\"width: 49.797%; text-align: center;\"><a href=\"https:\/\/pwonlyias.com\/stage\/quiz\/\" target=\"_blank\" rel=\"noopener\"><b>Daily Current Affairs Quiz<\/b><\/a><\/td>\n<td style=\"width: 61.393%; text-align: center;\"><a href=\"https:\/\/pwonlyias.com\/stage\/mains-answer-writing\/\" target=\"_blank\" rel=\"noopener\"><b>Daily Main Answer Writing<\/b><\/a><\/td>\n<\/tr>\n<tr>\n<td style=\"width: 49.797%; text-align: center;\"><a href=\"https:\/\/store.pw.live\/govt-entrance-exams\/upsc-books\/upsc-previous-year-papers?utm_source=SEO&#038;utm_medium=PW+Live&#038;utm_campaign=UPSC+Previous+Year+Papers\" target=\"_blank\" rel=\"noopener\"><b>Check Out Previous Years Papers From PW Store<\/b><\/a><\/td>\n<td style=\"width: 61.393%; text-align: center;\"><a href=\"https:\/\/pwonlyias.com\/stage\/upsc-test-series-courses\/\" target=\"_blank\" rel=\"noopener\"><b>UPSC Test Series<\/b><\/a><\/td>\n<\/tr>\n<tr>\n<td style=\"width: 49.797%; text-align: center;\"><a href=\"https:\/\/store.pw.live\/govt-entrance-exams\/upsc-books\/upsc-textbooks?utm_source=SEO&#038;utm_medium=PW+Live&#038;utm_campaign=UPSC+Textbooks\" target=\"_blank\" rel=\"noopener\"><b>Check Out UPSC NCERT Textbooks From PW Store<\/b><\/a><\/td>\n<td style=\"width: 61.393%; text-align: center;\"><a href=\"https:\/\/store.pw.live\/govt-entrance-exams\/upsc-books\/upsc-modules?utm_source=SEO&#038;utm_medium=PW+Live&#038;utm_campaign=UPSC+Modules\" target=\"_blank\" rel=\"noopener\"><b>Check Out UPSC Modules From PW Store<\/b><\/a><b>\u00a0<\/b><\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Core Demand of the Question Examine the affordability in India&#8217;s generic pharmaceutical landscape. Examine the limitation in balancing affordability with quality in India&#8217;s generic pharmaceutical landscape. Highlight the challenges posed by decentralized drug regulations, variations in manufacturing standards, and non-uniform enforcement mechanisms. Suggest a way ahead Answer India&#8217;s generic pharmaceutical sector, which supplies over 60%&hellip; <a class=\"more-link\" href=\"https:\/\/pwonlyias.com\/stage\/mains-answer-writing\/the-interplay-between-affordability-and-quality-in-indias-generic-pharmaceutical\">Continue reading <span class=\"screen-reader-text\">Critically examine the interplay between affordability and quality in India&#8217;s generic pharmaceutical landscape. Highlight the challenges posed by decentralized drug regulations, variations in manufacturing standards, and non-uniform enforcement mechanisms. (15 M, 250 words)<\/span><\/a><\/p>\n","protected":false},"author":11,"featured_media":0,"menu_order":0,"comment_status":"open","ping_status":"open","template":"","format":"standard","meta":{"rank_math_lock_modified_date":false,"footnotes":""},"paper-wise":[2084],"subject":[],"acf":[],"_links":{"self":[{"href":"https:\/\/pwonlyias.com\/stage\/wp-json\/wp\/v2\/mains-answer-writing\/147587"}],"collection":[{"href":"https:\/\/pwonlyias.com\/stage\/wp-json\/wp\/v2\/mains-answer-writing"}],"about":[{"href":"https:\/\/pwonlyias.com\/stage\/wp-json\/wp\/v2\/types\/mains-answer-writing"}],"author":[{"embeddable":true,"href":"https:\/\/pwonlyias.com\/stage\/wp-json\/wp\/v2\/users\/11"}],"replies":[{"embeddable":true,"href":"https:\/\/pwonlyias.com\/stage\/wp-json\/wp\/v2\/comments?post=147587"}],"version-history":[{"count":3,"href":"https:\/\/pwonlyias.com\/stage\/wp-json\/wp\/v2\/mains-answer-writing\/147587\/revisions"}],"predecessor-version":[{"id":147743,"href":"https:\/\/pwonlyias.com\/stage\/wp-json\/wp\/v2\/mains-answer-writing\/147587\/revisions\/147743"}],"wp:attachment":[{"href":"https:\/\/pwonlyias.com\/stage\/wp-json\/wp\/v2\/media?parent=147587"}],"wp:term":[{"taxonomy":"paper-wise","embeddable":true,"href":"https:\/\/pwonlyias.com\/stage\/wp-json\/wp\/v2\/paper-wise?post=147587"},{"taxonomy":"subject","embeddable":true,"href":"https:\/\/pwonlyias.com\/stage\/wp-json\/wp\/v2\/subject?post=147587"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}